Abstract:BACKGROUND:Gastric cancer (GC) represents a significant health burden with dire prognostic implications upon metastasis and recurrence. Pterostilbene (PTE) has been proven to have a strong ability to inhibit proliferation and metastasis in other cancers, while whether PTE exhibits anti-GC activity and its potential mechanism remain unclear.PURPOSE:To explore the efficacy and potential mechanism of PTE in treating GC.METHODS:We employed a comprehensive set of assays, including CCK-8, EdU staining, colony formation, flow cytometry, cell migration, and invasion assays, to detect the effect of PTE on the biological function of GC cells in vitro. The xenograft tumor model was established to evaluate the in vivo anti-GC activity of PTE. Network pharmacology was employed to predict PTE's potential targets and pathways within GC. Subsequently, Western blotting, immunofluorescence, and immunohistochemistry were utilized to analyze protein levels related to the cell cycle, EMT, and the JAK2/STAT3 pathway.RESULTS:Our study demonstrated strong inhibitory effects of PTE on GC cells both in vitro and in vivo. In vitro, PTE significantly induced cell cycle arrest at G0/G1 and S phases and suppressed proliferation, migration, and invasion of GC cells. In vivo, PTE led to a dose-dependent reduction in tumor volume and weight. Importantly, PTE exhibited notable safety, leaving mouse weight, liver function, and kidney function unaffected. The involvement of the JAK2/STAT3 pathway in PTE's anti-GC effect was predicted utilizing network pharmacology. PTE suppressed JAK2 kinase activity by binding to the JH1 kinase structural domain and inhibited the downstream STAT3 signaling pathway. Western blotting confirmed PTE's inhibition of the JAK2/STAT3 pathway and EMT-associated protein levels. The anti-GC effect was partially reversed upon STAT3 activation, validating the pivotal role of the JAK2/STAT3 signaling pathway in PTE's activity.CONCLUSION:Our investigation validates the potent inhibitory effects of PTE on the proliferation and metastasis of GC cells. Importantly, we present novel evidence implicating the JAK2/STAT3 pathway as the key mechanism through which PTE exerts its anti-GC activity. These findings not only establish the basis for considering PTE as a promising lead compound for GC therapeutics but also contribute significantly to our comprehension of the intricate molecular mechanisms underlying its exceptional anti-cancer properties.

Pterostilbene Inhibits MTA1/HDAC1 Complex Leading to PTEN Acetylation in Hepatocellular Carcinoma.

Tumoricidal Activities of Pterostilbene Depend Upon Destabilizing the MTA1-NuRD Complex and Enhancing P53 Acetylation in Hepatocellular Carcinoma

Pterostilbene Increases PTEN Expression Through the Targeted Downregulation of Microrna-19A in Hepatocellular Carcinoma

Mechanism of pterostilbene inhibiting growth of hepatocellular carcinoma by regulating metastasis-associated protein 1 expression

Pterostilbene Acts Through Metastasis-Associated Protein 1 To Inhibit Tumor Growth, Progression And Metastasis In Prostate Cancer

Natural product pectolinarigenin inhibits proliferation, induces apoptosis, and causes G2/M phase arrest of HCC via PI3K/AKT/mTOR/ERK signaling pathway.

Targeting MTA1/HIF-1α signaling by pterostilbene in combination with histone deacetylase inhibitor attenuates prostate cancer progression

Pterostilbene Simultaneously Induces Apoptosis, Cell Cycle Arrest and Cyto-Protective Autophagy in Breast Cancer Cells.

Pterostilbene induces pyroptosis of breast cancer cells, inhibits the growth and invasion of transplanted tumor and reshapes its tumor microenvironment

Pterostilbene Exerts Cytotoxicity on Activated Hepatic Stellate Cells by Inhibiting Excessive Proliferation Through the Crosstalk of Sirt1 and STAT3 Pathways.

Pterostilbene Inhibits Human Multiple Myeloma Cells Via ERK1/2 and JNK Pathway in Vitro and in Vivo.

Pterostilbene Inhibits Hepatocellular Carcinoma Proliferation and HBV Replication by Targeting Ribonucleotide Reductase M2 Protein.

Pterostilbene Exerts Antitumor Activity Via The Notch1 Signaling Pathway In Human Lung Adenocarcinoma Cells

Long Non-coding RNAs Contribute to the Inhibition of Proliferation and EMT by Pterostilbene in Human Breast Cancer

P53-dependent downregulation of hTERT protein expression and telomerase activity induces senescence in lung cancer cells as a result of pterostilbene treatment

The Antitumor Agent PBT-1 Directly Targets HSP90 and Hnrnp A2/B1 and Inhibits Lung Adenocarcinoma Growth and Metastasis

Pterostilbene Suppresses Gastric Cancer Proliferation and Metastasis by Inhibiting Oncogenic JAK2/STAT3 Signaling: in Vitro and in Vivo Therapeutic Intervention

C21 steroid-enriched fraction refined from Marsdenia tenacissima inhibits hepatocellular carcinoma through the coordination of Hippo-Yap and PTEN-PI3K/AKT signaling pathways.

Pterostilbene, an Active Constituent of Blueberries, Suppresses Proliferation Potential of Human Cholangiocarcinoma Via Enhancing the Autophagic Flux

Puerarin inhibits hepatocellular carcinoma invasion and metastasis through miR-21-mediated PTEN/AKT signaling to suppress the epithelial-mesenchymal transition

Pterostilbene modulates the suppression of multidrug resistance protein 1 and triggers autophagic and apoptotic mechanisms in cisplatin-resistant human oral cancer CAR cells via AKT signaling